Stockscreener 앱 받기
1.85
0.00%
0.00
시간 외 거래:
1.85
Adagene Inc Adr 주식(ADAG)의 최신 뉴스
Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World
FY2024 Earnings Forecast for Adagene Issued By HC Wainwright - MarketBeat
FY2029 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com
Adagene reports positive colorectal cancer trial results - Investing.com India
ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times
Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia
Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene to Present New ADG126-KEYTRUDA Combo Data for Colorectal Cancer at ASCO GI Symposium - StockTitan
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 - Wahanariau
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 - GlobeNewswire
Adagene Hosts Expert Panel on Breakthrough Cancer Treatment ADG126 for Colorectal Cancer - StockTitan
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Increases By 88.2% - MarketBeat
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Fmr LLC Has $2.84 Million Stock Holdings in Adagene Inc. (NASDAQ:ADAG) - Defense World
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Drops By 87.8% - Defense World
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Anheuser-Busch InBev S.A. ADR falls Tuesday, underperforms market - MSN
Adagene shares downgraded to hold, target cut to $3.50 - Investing.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat
Anheuser-Busch InBev S.A. ADR falls Friday, underperforms market - MSN
Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada
Adagene reports new findings at SITC meeting - Investing.com India
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau
Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times
Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN
HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat
Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World
5.49%
0.79%
자본화:
|
볼륨(24시간):